Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Maduck Sean
 2. Date of Event Requiring Statement (Month/Day/Year)
02/07/2018		 3. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [CORT]
(Last)
(First)
(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

MENLO PARK, CA 94025		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 10,024
D
 
Common Stock 10,000
I
See Footnote (1)
Common Stock 10,000
I
See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (3) 11/01/2022 Common Stock 45,000 $ 2.24 D  
Stock Option (Right to Buy)   (3) 01/30/2023 Common Stock 20,000 $ 2.08 D  
Stock Option (Right to Buy)   (3) 11/19/2023 Common Stock 25,000 $ 1.92 D  
Stock Option (Right to Buy)   (3) 02/06/2024 Common Stock 40,000 $ 3.02 D  
Stock Option (Right to Buy)   (4) 08/07/2024 Common Stock 100,000 $ 2.61 D  
Stock Option (Right to Buy)   (5) 02/18/2025 Common Stock 250,000 $ 3.29 D  
Stock Option (Right to Buy)   (6) 02/26/2026 Common Stock 150,000 $ 3.88 D  
Stock Option (Right to Buy)   (7) 05/02/2026 Common Stock 150,000 $ 5.05 D  
Stock Option (Right to Buy)   (8) 02/10/2027 Common Stock 400,000 $ 8.27 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Maduck Sean
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025		       See Remarks  

Signatures

/s/ Sean Maduck 02/09/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
(2) Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.
(3) Fully exercisable.
(4) Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of August 1, 2014, so that the total number of shares subject to this option becomes fully vested and exercisable on August 1, 2018.
(5) Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 18, 2015, so that the total number of shares subject to this option becomes fully vested and exercisable on February 18, 2019.
(6) Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 26, 2016, so that the total number of shares subject to this option becomes fully vested and exercisable on February 26, 2020.
(7) Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of April 27, 2016, so that the total number of shares subject to this option becomes fully vested and exercisable on April 27, 2020.
(8) Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 10, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 10, 2021.
 
Remarks:
Senior Vice President, Commercial

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.